{
  "title": "M21-1, Part V, Subpart iii, Chapter 12, Section C - Progressive Neurological Disorders",
  "url": "https://www.knowva.ebenefits.va.gov/system/templates/selfservice/va_ssnew/help/customer/locale/en-US/portal/554400000001018/content/554400000180833/M21-1-Part-V-Subpart-iii-Chapter-12-Section-C-Progressive-Neurological-Disorders",
  "content": "﻿﻿<-- Previous Section\nNext Section -->\nOverview\nIn This Section\nThis section contains the following topics:\nTopic\nTopic Name\n1\nMultiple Sclerosis (MS)\n2\nAmyotrophic Lateral Sclerosis (ALS)\n3\nParkinson’s Disease and Parkinsonism\n1\n.\nMS\nIntroduction\nThis topic contains information about MS, including\ndefinition of MS\nevaluating a residual MS disability 30 percent or more\nexample of evaluating residual MS disability 30 percent or more\n, and\npresumptive service connection (SC) for MS\n.\nChange Date\nApril 16, 2020\nV.iii.12.C.1.a\n.\nDefinition: MS\nMultiple sclerosis\n(MS) is a slowly progressive central nervous system disease, and is characterized by\ndisseminated patches of demyelination in the brain and spinal cord which cause multiple and varied neurologic symptoms and signs, and\nthe occurrence of remissions and exacerbations in the symptoms.\nV.iii.12.C.1.b\n.\nEvaluating a Residual MS Disability 30 Percent or More\nIn cases of MS\nevaluate each affected system or body part separately\nshow the diagnostic code (DC) for MS only once by listing it with the most severely affected function\ncode involvement of other manifestations thereafter under the DC assignable for the condition on which the evaluation is based, and\nshow the remaining conditions as secondary to MS.\nNotes\n:\nThis is a change from the previous requirement to evaluate MS as a single disability when the combined degree was less than 100 percent.\nIf the combined evaluation for all disabilities due to MS is 20 percent or less, assign a 30-percent evaluation under\n38 CFR 4.124a, DC 8018\n.\nImportant\n:  Readjudicate cases previously evaluated as a single disability as they are encountered under the procedure outlined above.\nV.iii.12.C.1.c\n.\nExample of Evaluating Residual MS Disability 30 Percent or More\nThis exhibit contains an example of evaluating a residual MS disability 30 percent or more.\nCoded Conclusion\n:\n1. SC (KC PRES)\n8018-7542\n40% from 12-10-19\nMultiple sclerosis with bladder dysfunction\n8520\n10% from 12-10-19\nWeakness of right lower extremity secondary to multiple sclerosis\n8520\n10% from 12-10-19\nWeakness of left lower extremity secondary to multiple sclerosis\n7599-7522\n0% from 12-10-19\nImpotency without penile deformity, secondary to multiple sclerosis\nCOMB:\n50% from 12-10-19\n43. Bilateral Factor of 1.9% added for diagnostic codes 8520 and 8520\nK-1\nEntitled to special monthly compensation under\n38 U.S.C. 1114\n, subsection (k) and\n38 CFR 3.350(a)\non account of loss of use of a creative organ from 12-10-19.\nNote\n:  Special monthly compensation (SMC) coding is 01-01-00-00-1.\nReference\n:  For more information on evaluating MS, see\nSuggested Diagnostic Codes for Parkinson's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS)\n.\nV.iii.12.C.1.d\n.\nPresumptive SC for MS\nPresumptive service connection (SC) may be established for MS if the disease becomes manifest within seven years from the date of separation.\nReference\n:  For more information on requirements for establishment of presumptive SC, see\n38 CFR 3.307(a)\n38 CFR 3.309\n, and\nM21-1, Part V, Subpart ii, 2.B\n.\n2\n.\nALS\nIntroduction\nThis topic contains information about ALS, including\ndefinition of ALS\nestablishing presumptive SC for ALS\nassigning a 100-percent minimum evaluation for ALS\nevaluation guidelines for ALS\nALS and ancillary benefits\n, and\nauthority to decide ALS claims\n.\nChange Date\nFebruary 15, 2023\nV.iii.12.C.2.a\n.\nDefinition: ALS\nAmyotrophic lateral sclerosis\n(ALS), also called Lou Gehrig’s disease, is a neuromuscular disease that causes degeneration of nerve cells in the brain and spinal cord, resulting in muscle weakness, muscle atrophy, and spontaneous muscle activity.\nV.iii.12.C.2.b\n.\nEstablishing Presumptive SC for ALS\nEffective September 23, 2008,\n38 CFR 3.318\nestablished a presumption of SC for ALS manifested at any time after discharge or release from active military, naval, air, or space service.\nExceptions\n:  SC will not be established if\nthere is affirmative evidence that ALS was\nnot incurred or aggravated by military, naval, or air service, or\nwas due to the Veteran’s own willful misconduct;\nor\nif the Veteran did not have active, continuous service of 90 days or more.\nIn\nBowers v. Shinseki\n, 748 F.3d. 1351 (Fed. Cir., 2014), the Federal Circuit held that active duty for training does not qualify as active military, naval, air, or space service for the purpose of establishing entitlement to SC for ALS on a presumptive basis.\nNote\n:  Primary lateral sclerosis (PLS) is\nnot\nconsidered to be a qualifying\ndisease under\n38 CFR 3.318\n.  Because PLS and ALS are diseases of the nervous system and both affect motor neurons, treating physicians may not be able to identify whether the Veteran has PLS or ALS in the initial stages.  If the diagnosis is uncertain after reviewing the medical evidence, request a medical opinion with examiner review of\nall\npertinent evidence in the claims folder.\nThis was considered a liberalizing regulation.  Therefore consider the application of\n38 CFR 3.114(a)\nwhen granting presumptive SC for ALS under the provisions of\n38 CFR 3.318\n.\nReferences\n:  For more information on\nliberalizing changes of law and Department of Veterans Affairs (VA) issuances, see\nM21-1, Part V, Subpart ii, 4.A.6\nauthority to decide ALS claims, see\nM21-1, Part V, Subpart iii, 12.C.2.f\n, and\nactive duty service for establishing entitlement to SC for ALS on a presumptive basis, see\nHansen-Sorensen v. Wilkie\n, 909 F.3d 1379 (Fed. Cir. 2018).\nV.iii.12.C.2.c\n.\nAssigning a 100 Percent Minimum Evaluation for ALS\nALS is evaluated under\n38 CFR 4.124a, DC 8017\n.\nEffective January 19, 2012, the diagnostic criteria for ALS were amended in\n38 CFR 4.124a\nto provide a 100-percent evaluation for any Veteran with service-connected (SC) ALS.  A diagnosis of ALS alone is sufficient to support an evaluation of 100 percent.  A total disability evaluation is the minimum evaluation to be assigned for ALS because of the possibility of SMC and automatic entitlement to ancillary benefits.\nNote\n:  This rule will be applied to all cases pending before VA on or after, January 19, 2012, and\ndoes\nconstitute a liberalizing VA regulation under\n38 U.S.C. 5110(g)\nand\n38 CFR 3.114\nfor the purpose of determinations of effective dates and retroactive benefits.\nV.iii.12.C.2.d\n.\nEvaluation Guidelines for ALS\nDetermine the proper evaluation for all complications of ALS prior to coding a single 100-percent evaluation under\n38 CFR 4.124a, DC 8017\n.  Refer to the table below for guidance.\nIf ...\nThen ...\nthere is no complication warranting a single 100-percent evaluation\nassign a 100-percent evaluation under\n38 CFR 4.124a, DC 8017\n, and\ninclude all compensable complications in the description of the diagnosis.\nExample\n:  ALS with loss of use of the left foot and partial ninth cranial nerve paralysis.\na single 100-percent evaluation is warranted for a complication of ALS\nassign a 100-percent evaluation for that complication.\nUse a hyphenated DC.\nExample\n:  8017-5110, loss of use of both feet.\nSeparately evaluate additional complications.\nDo not assign a separate evaluation under\n38 CFR 4.124a, DC 8017\nalone; this would be pyramiding under\n38 CFR 4.14\n.\nNote\n:  A 100-percent evaluation for a complication of ALS satisfies the policy that all ALS awards will be assigned at least a 100-percent evaluation.\nReference\n:  For more information on evaluating ALS, see\nSuggested Diagnostic Codes for Parkinson's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS)\n.\nV.iii.12.C.2.e\n.\nALS and Ancillary Benefits\nConsider eligibility for SMC and/or other ancillary benefits in all ALS cases.\nEnsure the\nCodesheet\nreflects all complications that can be separately evaluated.\nEntitlement to SMC at the statutory housebound rate may be warranted when\nALS and complications are assigned one 100-percent evaluation under\n38 CFR 4.124a, DC 8017\nand the combined evaluation of other SC conditions totals 60 percent or higher, or\nan ALS complication is evaluated as 100-percent disabling and the combined evaluation of other SC conditions, including additional separately evaluated complications of ALS, total 60 percent or higher.\nEntitlement to SMC, such as SMC K for loss of use of a foot, may still be warranted when one total disability evaluation is assigned for ALS and all complications under\n38 CFR 4.124a, DC 8017\n.\nEffective December 3, 2013,\n38 C.F.R. 3.809d\nprovides that SC ALS is a qualifying condition for the purpose of entitlement to specially adapted housing.\nEffective February 25, 2015,\n38 CFR 3.808\nprovides that SC ALS is a qualifying condition for entitlement to a certificate of eligibility for automobile or other conveyance and adaptive equipment.  The amendment applies to all applications pending before VA on, or received after, February 25, 2015.\nReferences\n:  For more information on\nSMC, see\nM21-1, Part VIII, Subpart iv, 4.A\nancillary benefits, see\nM21-1, Part I, Subpart ii, 2.4\nautomobile allowance and adaptive equipment, see\nM21-1, Part XIII, Subpart i, 2.A\n, and\nspecially adapted housing or special housing adaptation grants, see\nM21-1, Part XIII, Subpart i, 2.B\n.\nV.iii.12.C.2.f\n.\nAuthority to Decide ALS Claims\nAll claims involving ALS and/or related complications must be reviewed/rated by a Rating Veterans Service Representative designated as an ALS specialist.\n3\n.\nParkinson's Disease and Parkinsonism\nIntroduction\nThis topic contains information on Parkinson’s disease, including\ndefinition of\nParkinson’s disease\n, and\nParkinsonism\nSC for Parkinson’s disease and Parkinsonism\nevaluating Parkinson’s disease and Parkinsonism\n, and\nSMC and Parkinson’s disease/Parkinsonism\n.\nChange Date\nJune 21, 2021\nV.iii.12.C.3.a\n.\nDefinition: Parkinson’s Disease\nParkinson’s disease\nis a chronic, slowly progressive central nervous system disorder characterized by muscular rigidity, a tremor of resting muscles, slow and decreased voluntary movements and positional instability.  An outdated term for Parkinson’s disease is paralysis agitans.\nEarly signs and symptoms of the condition may include:\ninfrequent blinking\nlack of facial expression\ndecreased movement, and\nimpaired postural reflexes.\nThe condition is characterized by muscle tremors at rest which diminish during movement and are absent during sleep.  The tremors are enhanced by emotional tension or fatigue and the hands are most affected. Muscle rigidity may be present without tremors.  As the muscle rigidity progresses, movement becomes slow (bradykinesia), decreased or diminished (hypokinesia), and difficult to initiate (akinesia).  Other signs and symptoms may include:\nmuscular aches and fatigue\nmask-like expression with open mouth\ndrooling\nstooped posture\ngait characterized by involuntary, short, accelerating steps\ndifficulty in walking\nloss of postural reflexes (tendency to fall forward or backward with respective shift in center of gravity)\nspeech manifestations – specifically low speech volume with stuttering or slurred speech, or uniformity of tone and high pitch, and\ndysphagia.\nV.iii.12.C.3.b\n.\nDefinition: Parkinsonism\nParkinsonism is a disease process separate and distinct from Parkinson’s disease.  Also called\natypical Parkinson’s disease or Parkinson’s plus\n, it is a general term that refers to a group of neurological disorders that cause movement problems similar to those seen in Parkinson’s disease, as discussed in\nM21-1, Part V, Subpart iii, 12.C.3.a\n.\nV.iii.12.C.3.c\n.\nSC for Parkinson’s Disease and Parkinsonism\nParkinson’s disease or Parkinsonism can be directly incurred in service, but in most cases, either will be SC on a presumptive or secondary basis.\nParalysis agitans is listed as a chronic disease in\n38 CFR 3.309(a)\nand as such Parkinson’s disease is presumed to have had its inception in service if manifested to a compensable degree within one year of discharge under\n38 CFR 3.307(a)(3)\n.\nParkinson’s disease is listed as a disease associated with exposure to certain herbicide agents in\n38 CFR 3.309(e)\nand therefore is presumed to be related to herbicide exposure in the Republic of Vietnam (RVN) when manifested to a compensable degree at any time after service as provided in\n38 CFR 3.307(a)(6)\nor\n38 U.S.C. 1116A\n.\nPublic Law 116-283, William M. (Mac) Thornberry National Defense Authorization Act for Fiscal Year 2021\n, effective January 1, 2021, established a presumption of SC for Parkinsonism as related to herbicide exposure in the RVN when manifested to a compensable degree at any time after service as provided in\n38 CFR 3.307(a)(6)\nor\n38 U.S.C. 1116A\n.\nFinally, under\n38 CFR 3.310(d)\n, Parkinson’s disease and/or Parkinsonism is treated as secondary to traumatic brain injury (TBI) when the TBI was moderate or severe.\nReferences\n:  For more information on\npresumptive SC, see\nM21-1, Part V, Subpart ii, 2.B\nconditions presumptively related to herbicide exposure in the RVN, see\n39 CFR 3.309(e)\n, and\nM21-1, Part VIII, Subpart i\nsecondary SC of conditions related to TBI, see\nM21-1, Part V, Subpart iii, 12.B\nconsidering whether a medical diagnosis has probative value, see\nM21-1, Part V, Subpart ii, 1.A\ndetermining whether to require further development, see\nM21-1, Part V, Subpart ii, 3.B.1.a\n, and\ndetermining whether examinations are insufficient for rating purposes and obtaining clarification, see\nM21-1, Part IV, Subpart i, 3.C\n.\nV.iii.12.C.3.d\n.\nEvaluating Parkinson’s Disease and Parkinsonism\nEvaluate\nParkinson's disease using the diagnostic criteria for paralysis agitans under\n38 CFR. 4.124a, DC 8004\n, and\nParkinsonism by analogy to paralysis agitans under\n38 CFR. 4.124a, DC 8004\n, using DC 8099-8004.\nUse the same rating guidance as for MS as provided in\nM21-1, Part V, Subpart iii, 12.C.1.b\n.\nReference\n:  For more information on evaluating Parkinson’s disease, see\nSuggested Diagnostic Codes for Parkinson's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS)\n.\nV.iii.12.C.3.e\n.\nSMC and Parkinson’s Disease/\nParkinsonism\nGive careful consideration to SMC in cases of Parkinson’s disease and/or Parkinsonism, particularly losses of use and aid and attendance (A&A).\nReferences\n:  For more information on\nloss of use, see\nM21-1, Part VIII, Subpart iv, 4.A.4\n, and\nthe level of disability required for entitlement to A&A, see\nM21-1, Part VIII, Subpart iv, 4.A.8.b\n.\n﻿﻿\n<-- Previous Section\nNext Section -->\nTo Top",
  "content_html": "<div class=\"article-content\">\n<div compile-custom=\"article.content\" ng-aria=\"articleContent\"><p class=\"ng-scope\"></p><div class=\"ng-scope\" style=\"text-align: right\"><span style=\"font-size: 11px\"><span style=\"font-family: arial, helvetica, sans-serif\"><a articleid=\"554400000180832\" articlename=\"M21-1, Part V, Subpart iii, Chapter 12, Section B - Traumatic Brain Injury (TBI)\" articleviewcontext=\"article_view_related_article\" class=\"eGainArticleLink\" eg-link-click=\"\" href=\"/system/templates/selfservice/va_ssnew/help/customer/locale/en-US/portal/554400000001018/content/554400000180832/M21-1-Part-V-Subpart-iii-Chapter-12-Section-B-Traumatic-Brain-Injury-TBI\">﻿﻿&lt;-- Previous Section</a>  <a articleid=\"554400000180520\" articlename=\"M21-1, Part V, Subpart iii, Chapter 13 - Mental Disorders\" articleviewcontext=\"article_view_related_article\" class=\"eGainArticleLink\" eg-link-click=\"\" href=\"/system/templates/selfservice/va_ssnew/help/customer/locale/en-US/portal/554400000001018/content/554400000180520/M21-1-Part-V-Subpart-iii-Chapter-13-Mental-Disorders\">Next Section --&gt;</a></span></span></div><h2 class=\"ng-scope\"><span style=\"font-family: arial, helvetica, sans-serif\"><a id=\"top\" name=\"top\"><span style=\"font-size: 16px\">Overview</span></a></span></h2><div class=\"ng-scope\"> <br/> </div><div class=\"ng-scope\" style=\"margin-left: 85pt\"><hr/></div><div class=\"ng-scope\" style=\"height: 8px; width: 15px; vertical-align: top\"></div><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"ng-scope\" style=\"border-spacing: 0px; border-collapse: revert;\"><tbody><tr><td style=\"height: 16px; width: 115px; vertical-align: top; padding: 0px;\"><h3><span style=\"font-family: arial, helvetica, sans-serif\"><span style=\"font-size: 14px\">In This Section</span></span></h3></td><td style=\"height: 16px; width: 15px; vertical-align: top; padding: 0px;\"></td><td style=\"height: 16px; width: 516px; padding: 0px;\"><div><span style=\"font-family: arial, helvetica, sans-serif\"><span style=\"font-size: 14px\"> This section contains the following topics:</span></span></div><div><span style=\"font-family: arial, helvetica, sans-serif\"><span style=\"font-size: 14px\"> </span></span></div><table border=\"1\" cellpadding=\"1\" cellspacing=\"1\" style=\"width: 499px; border-spacing: 1px; border-collapse: revert;\" summary=\"Column 1 has the topic number and column 2 has the topic title.\"><thead><tr><th scope=\"col\" style=\"width: 86px; padding: 1px;\"><div style=\"text-align: center\"><span style=\"font-family: arial, helvetica, sans-serif\"><span style=\"font-size: 14px\"><strong>Topic</strong></span></span></div></th><th scope=\"col\" style=\"width: 423px; padding: 1px;\"><div style=\"text-align: center\"><span style=\"font-family: arial, helvetica, sans-serif\"><span style=\"font-size: 14px\"><strong>Topic Name</strong></span></span></div></th></tr></thead><tbody><tr><td style=\"width: 86px; padding: 1px;\"><div align=\"center\"><span style=\"font-family: arial, helvetica, sans-serif\"><span style=\"font-size: 14px\">1 </span></span></div></td><td style=\"width: 423px; padding: 1px;\"><div><span style=\"font-family: arial, helvetica, sans-serif\"><a href=\"#1\" target=\"_self\"><span style=\"font-size: 14px\">Multiple Sclerosis (MS)</span></a></span></div></td></tr><tr><td style=\"width: 86px; vertical-align: middle; padding: 1px;\"><div align=\"center\"><span style=\"font-family: arial, helvetica, sans-serif\"><span style=\"font-size: 14px\">2</span></span></div></td><td style=\"width: 423px; padding: 1px;\"><div><span style=\"font-family: arial, helvetica, sans-serif\"><a href=\"#2\" target=\"_self\"><span style=\"font-size: 14px\">Amyotrophic Lateral Sclerosis (ALS)</span></a></span></div></td></tr><tr><td style=\"width: 86px; padding: 1px;\"><div align=\"center\"><span style=\"font-family: arial, helvetica, sans-serif\"><span style=\"font-size: 14px\">3</span></span></div></td><td style=\"width: 423px; padding: 1px;\"><div><span style=\"font-family: arial, helvetica, sans-serif\"><a href=\"#3\" target=\"_self\"><span style=\"font-size: 14px\">Parkinson’s Disease and Parkinsonism</span></a></span></div></td></tr></tbody></table><div></div></td></tr></tbody></table><div class=\"ng-scope\" style=\"margin-left: 85pt\"><hr/></div><div class=\"ng-scope\"><br/><span style=\"font-family: arial, helvetica, sans-serif\"> </span></div><h2 class=\"ng-scope\"><span style=\"font-family: arial, helvetica, sans-serif\"><span style=\"font-size: 16px\">1<a id=\"1\" name=\"1\">.</a>  MS</span></span></h2><div class=\"ng-scope\"><br/><span style=\"font-family: arial, helvetica, sans-serif\"> </span></div><div class=\"ng-scope\" style=\"margin-left: 85pt\"><hr/></div><div class=\"ng-scope\" style=\"height: 8px; width: 15px\"></div><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"ng-scope\" style=\"border-spacing: 0px; border-collapse: revert;\"><tbody><tr><td style=\"width: 115px; vertical-align: top; padding: 0px;\"><h3><span style=\"font-family: arial, helvetica, sans-serif\"><span style=\"font-size: 14px\">Introduction</span></span></h3></td><td style=\"width: 15px; vertical-align: top; padding: 0px;\"></td><td style=\"width: 516px; padding: 0px;\"><div><span style=\"font-family: arial, helvetica, sans-serif\"><span style=\"font-size: 14px\">This topic contains information about MS, including</span></span></div><ul><li><div><span style=\"font-family: arial, helvetica, sans-serif\"><a href=\"#1a\" target=\"_self\"><span style=\"font-size: 14px\">definition of MS</span></a></span></div></li><li><div><span style=\"font-family: arial, helvetica, sans-serif\"><a href=\"#1b\" target=\"_self\"><span style=\"font-size: 14px\">evaluating a residual MS disability 30 percent or more</span></a></span></div></li><li><div><span style=\"font-family: arial, helvetica, sans-serif\"><span style=\"font-size: 14px\"><a href=\"#1c\" target=\"_self\">example of evaluating residual MS disability 30 percent or more</a>, and</span></span></div></li><li><div><span style=\"font-family: arial, helvetica, sans-serif\"><span style=\"font-size: 14px\"><a href=\"#1d\" target=\"_self\">presumptive service connection (SC) for MS</a>.</span></span></div></li></ul></td></tr></tbody></table><div class=\"ng-scope\" style=\"margin-left: 85pt\"><hr/></div><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"ng-scope\" style=\"border-spacing: 0px; border-collapse: revert;\"><tbody><tr><td style=\"width: 115px; vertical-align: top; padding: 0px;\"><h3><span style=\"font-family: arial, helvetica, sans-serif\"><strong><span style=\"font-size: 14px\">Change Date</span></strong></span></h3></td><td style=\"width: 15px; vertical-align: top; padding: 0px;\"></td><td style=\"width: 516px; padding: 0px;\"><div><span style=\"font-family: arial, helvetica, sans-serif\"><span style=\"font-size: 14px\">April 16, 2020</span></span></div></td></tr></tbody></table><div class=\"ng-scope\" style=\"margin-left: 85pt\"><hr/></div><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"ng-scope\" style=\"border-spacing: 0px; border-collapse: revert;\"><tbody><tr><td style=\"width: 115px; vertical-align: top; padding: 0px;\"><h3><span style=\"font-family: arial, helvetica, sans-serif\"><span style=\"font-size: 14px\">V.iii.12.C.1.a<a id=\"1a\" name=\"1a\">.</a>   Definition: MS</span></span></h3></td><td style=\"width: 15px; vertical-align: top; padding: 0px;\"></td><td style=\"width: 516px; padding: 0px;\"><div><span style=\"font-family: arial, helvetica, sans-serif\"><span style=\"font-size: 14px\"><strong><em>Multiple sclerosis </em></strong>(MS) is a slowly progressive central nervous system disease, and is characterized by</span></span></div><ul><li><div><span style=\"font-family: arial, helvetica, sans-serif\"><span style=\"font-size: 14px\">disseminated patches of demyelination in the brain and spinal cord which cause multiple and varied neurologic symptoms and signs, and</span></span></div></li><li><div><span style=\"font-family: arial, helvetica, sans-serif\"><span style=\"font-size: 14px\">the occurrence of remissions and exacerbations in the symptoms.</span></span></div></li></ul></td></tr></tbody></table><div class=\"ng-scope\" style=\"margin-left: 85pt\"><hr/></div><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"ng-scope\" style=\"border-spacing: 0px; border-collapse: revert;\"><tbody><tr><td style=\"width: 115px; vertical-align: top; padding: 0px;\"><h3><span style=\"font-family: arial, helvetica, sans-serif\"><span style=\"font-size: 14px\">V.iii.12.C.1.b<a id=\"1b\" name=\"1b\">.</a>  Evaluating a Residual MS Disability 30 Percent or More</span></span></h3></td><td style=\"width: 15px; vertical-align: top; padding: 0px;\"></td><td style=\"width: 516px; padding: 0px;\"><div><span style=\"font-family: arial, helvetica, sans-serif\"><span style=\"font-size: 14px\">In cases of MS</span></span></div><ul><li><div><span style=\"font-family: arial, helvetica, sans-serif\"><span style=\"font-size: 14px\">evaluate each affected system or body part separately</span></span></div></li><li><div><span style=\"font-family: arial, helvetica, sans-serif\"><span style=\"font-size: 14px\">show the diagnostic code (DC) for MS only once by listing it with the most severely affected function</span></span></div></li><li><div><span style=\"font-family: arial, helvetica, sans-serif\"><span style=\"font-size: 14px\">code involvement of other manifestations thereafter under the DC assignable for the condition on which the evaluation is based, and</span></span></div></li><li><div><span style=\"font-family: arial, helvetica, sans-serif\"><span style=\"font-size: 14px\">show the remaining conditions as secondary to MS.</span></span></div></li></ul><div><span style=\"font-family: arial, helvetica, sans-serif\"><span style=\"font-size: 14px\"><strong><em>Notes</em></strong>: </span></span></div><ul><li><div><span style=\"font-family: arial, helvetica, sans-serif\"><span style=\"font-size: 14px\">This is a change from the previous requirement to evaluate MS as a single disability when the combined degree was less than 100 percent.</span></span></div></li><li><div><span style=\"font-family: arial, helvetica, sans-serif\"><span style=\"font-size: 14px\">If the combined evaluation for all disabilities due to MS is 20 percent or less, assign a 30-percent evaluation under <a href=\"http://www.ecfr.gov/cgi-bin/text-idx?SID=061a0b481382fdc4ff5c1697742e7858&amp;node=se38.1.4_1124a&amp;rgn=div8\" target=\"_blank\">38 CFR 4.124a, DC 8018</a>.</span></span></div></li></ul><div><span style=\"font-family: arial, helvetica, sans-serif\"><span style=\"font-size: 14px\"><strong><em>Important</em></strong>:  Readjudicate cases previously evaluated as a single disability as they are encountered under the procedure outlined above.</span></span></div></td></tr></tbody></table><div class=\"ng-scope\" style=\"margin-left: 85pt\"><hr/></div><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"ng-scope\" style=\"border-spacing: 0px; border-collapse: revert;\"><tbody><tr><td style=\"width: 115px; vertical-align: top; padding: 0px;\"><h3><span style=\"font-family: arial, helvetica, sans-serif\"><span style=\"font-size: 14px\">V.iii.12.C.1.c<a id=\"1c\" name=\"1c\">.</a>  Example of Evaluating Residual MS Disability 30 Percent or More</span></span></h3></td><td style=\"width: 15px; vertical-align: top; padding: 0px;\"></td><td style=\"width: 516px; padding: 0px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">This exhibit contains an example of evaluating a residual MS disability 30 percent or more.</span></span></div><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"> </span></span></div><div></div><table border=\"1\" cellpadding=\"1\" cellspacing=\"1\" style=\"border-spacing: 1px; border-collapse: revert;\" summary=\"This is an example of evaluating residual MS disability 30 percent or more.\"><tbody><tr><td style=\"width: 167px; padding: 1px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><strong><em>Coded Conclusion</em></strong>:</span></span></div></td></tr><tr><td style=\"width: 167px; padding: 1px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">1. SC (KC PRES)</span></span></div></td></tr><tr><td style=\"width: 167px; padding: 1px;\"><div><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">8018-7542</span></span></div><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">40% from 12-10-19</span></span></div></div></td><td style=\"width: 336px; padding: 1px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">Multiple sclerosis with bladder dysfunction</span></span></div></td></tr><tr><td style=\"width: 167px; padding: 1px;\"><div><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">8520</span></span></div><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">10% from 12-10-19</span></span></div></div></td><td style=\"width: 336px; padding: 1px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">Weakness of right lower extremity secondary to multiple sclerosis</span></span></div></td></tr><tr><td style=\"width: 167px; padding: 1px;\"><div><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">8520</span></span></div><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">10% from 12-10-19</span></span></div></div></td><td style=\"width: 336px; padding: 1px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">Weakness of left lower extremity secondary to multiple sclerosis</span></span></div></td></tr><tr><td style=\"width: 167px; padding: 1px;\"><div><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">7599-7522</span></span></div><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">0% from 12-10-19</span></span></div></div></td><td style=\"width: 336px; padding: 1px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">Impotency without penile deformity, secondary to multiple sclerosis</span></span></div></td></tr><tr><td style=\"width: 167px; padding: 1px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">COMB:</span></span></div></td><td style=\"width: 336px; padding: 1px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">50% from 12-10-19</span></span></div></td></tr></tbody></table><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"> </span></span></div><div><table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-spacing: 0px; border-collapse: revert;\"><tbody><tr><td style=\"height: 18px; width: 503px; padding: 0px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">43. Bilateral Factor of 1.9% added for diagnostic codes 8520 and 8520</span></span></div></td></tr></tbody></table></div><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"> </span></span></div><table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-spacing: 0px; border-collapse: revert;\"><tbody><tr><td style=\"height: 18px; width: 59px; padding: 0px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">K-1</span></span></div></td><td style=\"height: 18px; width: 444px; padding: 0px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">Entitled to special monthly compensation under <a href=\"https://www.law.cornell.edu/uscode/text/38/1114\" target=\"_blank\">38 U.S.C. 1114</a>, subsection (k) and <a href=\"http://www.ecfr.gov/cgi-bin/text-idx?SID=e296a722064811bf99fb83cca8e57a8b&amp;mc=true&amp;node=se38.1.3_1350&amp;rgn=div8\" target=\"_blank\">38 CFR 3.350(a)</a> on account of loss of use of a creative organ from 12-10-19.</span></span></div></td></tr></tbody></table><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><strong><em> </em></strong></span></span></div><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><strong><em>Note</em></strong>:  Special monthly compensation (SMC) coding is 01-01-00-00-1.</span></span></div><div></div><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><strong><em>Reference</em></strong>:  For more information on evaluating MS, see <a href=\"https://vbaw.vba.va.gov/bl/21/rating/rat00.htm\" target=\"_blank\"><em>Suggested Diagnostic Codes for Parkinson's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS)</em></a>.</span></span></div></td></tr></tbody></table><div class=\"ng-scope\" style=\"margin-left: 85pt\"><hr/></div><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"ng-scope\" style=\"height: 111px; width: 687px; border-spacing: 0px; border-collapse: revert;\" width=\"687\"><tbody><tr><td style=\"height: 95px; width: 115px; padding: 0px;\"><h3><span style=\"font-family: arial, helvetica, sans-serif\"><span style=\"font-size: 14px\">V.iii.12.C.1.d<a id=\"1d\" name=\"1d\">.</a> Presumptive SC for MS</span></span></h3></td><td style=\"height: 95px; width: 15px; padding: 0px;\"></td><td style=\"height: 95px; width: 516px; padding: 0px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\">Presumptive service connection (SC) may be established for MS if the disease becomes manifest within seven years from the date of separation.</span></span></div><div><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\"><strong><em> </em></strong></span></span></div><div><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\"><strong><em>Reference</em></strong>:  For more information on requirements for establishment of presumptive SC, see </span></span></div><ul><li><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\"><a href=\"http://www.ecfr.gov/cgi-bin/text-idx?SID=061a0b481382fdc4ff5c1697742e7858&amp;node=se38.1.3_1307&amp;rgn=div8\" target=\"_blank\">38 CFR 3.307(a)</a></span></span></li><li><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\"><a href=\"http://www.ecfr.gov/cgi-bin/text-idx?SID=039d52e6f928e64a4c69be720bd18f4e&amp;mc=true&amp;node=se38.1.3_1309&amp;rgn=div8\" target=\"_blank\">38 CFR 3.309</a>, and </span></span></li><li><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\"><a articleid=\"554400000180482\" articlename=\"M21-1, Part V, Subpart ii, Chapter 2, Section B - Presumptive Service Connection (SC)\" articleviewcontext=\"article_view_related_article\" class=\"eGainArticleLink\" eg-link-click=\"\" href=\"/system/templates/selfservice/va_ssnew/help/customer/locale/en-US/portal/554400000001018/content/554400000180482/M21-1-Part-V-Subpart-ii-Chapter-2-Section-B-Presumptive-Service-Connection-SC\">M21-1, Part V, Subpart ii, 2.B</a>.</span></span></li></ul></td></tr></tbody></table><div class=\"ng-scope\" style=\"margin-left: 85pt\"><hr/></div><div class=\"ng-scope\"><br/><span style=\"font-family: arial, helvetica, sans-serif\"> </span></div><h2 class=\"ng-scope\"><span style=\"font-family: arial, helvetica, sans-serif\"><span style=\"font-size: 16px\"><strong>2<a id=\"2\" name=\"2\">.</a>  ALS</strong></span></span></h2><div class=\"ng-scope\" style=\"margin-left: 85pt\"><br/><span style=\"font-family: arial, helvetica, sans-serif\"> </span></div><div class=\"ng-scope\" style=\"margin-left: 85pt\"><hr/></div><div class=\"ng-scope\" style=\"height: 8px; width: 15px\"></div><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"ng-scope\" style=\"border-spacing: 0px; border-collapse: revert;\"><tbody><tr><td style=\"width: 115px; vertical-align: top; padding: 0px;\"><h3><span style=\"font-family: arial, helvetica, sans-serif\"><span style=\"font-size: 14px\"><strong>Introduction</strong></span></span></h3></td><td style=\"width: 15px; vertical-align: top; padding: 0px;\"></td><td style=\"width: 516px; padding: 0px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">This topic contains information about ALS, including</span></span></div><ul><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><a href=\"#2a\" target=\"_self\">definition of ALS</a></span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><a href=\"#2b\" target=\"_self\">establishing presumptive SC for ALS</a></span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><a href=\"#2c\" target=\"_self\">assigning a 100-percent minimum evaluation for ALS</a></span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><a href=\"#2d\" target=\"_self\">evaluation guidelines for ALS</a></span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><a href=\"#2e\" target=\"_self\">ALS and ancillary benefits</a>, and</span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><a href=\"#2f\" target=\"_self\">authority to decide ALS claims</a>.</span></span></div></li></ul></td></tr></tbody></table><div class=\"ng-scope\" style=\"margin-left: 85pt\"><hr/></div><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"ng-scope\" style=\"border-spacing: 0px; border-collapse: revert;\"><tbody><tr><td style=\"width: 115px; vertical-align: top; padding: 0px;\"><h3><span style=\"font-family: arial, helvetica, sans-serif\"><strong><span style=\"font-size: 14px\">Change Date</span></strong></span></h3></td><td style=\"width: 15px; vertical-align: top; padding: 0px;\"></td><td style=\"width: 516px; padding: 0px;\"><div><span style=\"font-family: arial, helvetica, sans-serif\"><span style=\"font-size: 14px\">February 15, 2023</span></span></div></td></tr></tbody></table><div class=\"ng-scope\" style=\"margin-left: 85pt\"><hr/></div><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"ng-scope\" style=\"border-spacing: 0px; border-collapse: revert;\"><tbody><tr><td style=\"width: 115px; vertical-align: top; padding: 0px;\"><h3><span style=\"font-family: arial, helvetica, sans-serif\"><span style=\"font-size: 14px\">V.iii.12.C.2.a<a id=\"2a\" name=\"2a\">.</a>  Definition: ALS</span></span></h3></td><td style=\"width: 15px; vertical-align: top; padding: 0px;\"></td><td style=\"width: 516px; padding: 0px;\"><div><span style=\"font-family: arial, helvetica, sans-serif\"><span style=\"font-size: 14px\"><strong><em>Amyotrophic lateral sclerosis</em></strong> (ALS), also called Lou Gehrig’s disease, is a neuromuscular disease that causes degeneration of nerve cells in the brain and spinal cord, resulting in muscle weakness, muscle atrophy, and spontaneous muscle activity.</span></span></div></td></tr></tbody></table><div class=\"ng-scope\" style=\"margin-left: 85pt\"><hr/></div><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"ng-scope\" style=\"border-spacing: 0px; border-collapse: revert;\"><tbody><tr><td style=\"width: 115px; vertical-align: top; padding: 0px;\"><h3><span style=\"font-family: arial, helvetica, sans-serif\"><span style=\"font-size: 14px\">V.iii.12.C.2.b<a id=\"2b\" name=\"2b\">.</a>  Establishing Presumptive SC for ALS</span></span></h3></td><td style=\"width: 15px; vertical-align: top; padding: 0px;\"></td><td style=\"width: 516px; padding: 0px;\"><div><div><span style=\"font-family: arial, helvetica, sans-serif\"><span style=\"font-size: 14px\">Effective September 23, 2008, <a href=\"http://www.ecfr.gov/cgi-bin/text-idx?SID=061a0b481382fdc4ff5c1697742e7858&amp;node=se38.1.3_1318&amp;rgn=div8\" target=\"_blank\">38 CFR 3.318</a> established a presumption of SC for ALS manifested at any time after discharge or release from active military, naval, air, or space service. </span></span></div><div><span style=\"font-family: arial, helvetica, sans-serif\"><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><span style=\"font-size: 14px\"><strong><em> </em></strong></span></span></span></span></div><div><span style=\"font-family: arial, helvetica, sans-serif\"><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><span style=\"font-size: 14px\"><strong><em>Exceptions</em></strong>:  SC will not be established if</span></span></span></span></div><ul><li><div><span style=\"font-family: arial, helvetica, sans-serif\"><span style=\"font-size: 14px\">there is affirmative evidence that ALS was</span></span></div><ul><li><div><span style=\"font-family: arial, helvetica, sans-serif\"><span style=\"font-size: 14px\">not incurred or aggravated by military, naval, or air service, or</span></span></div></li><li><div><span style=\"font-family: arial, helvetica, sans-serif\"><span style=\"font-size: 14px\">was due to the Veteran’s own willful misconduct;<strong><em> or</em></strong></span></span></div></li></ul></li><li><div><span style=\"font-family: arial, helvetica, sans-serif\"><span style=\"font-size: 14px\">if the Veteran did not have active, continuous service of 90 days or more.</span></span></div></li></ul><div><span style=\"font-family: arial, helvetica, sans-serif\"><span style=\"font-size: 14px\">In <a articleid=\"554400000014419\" articlename=\"Bowers v. Shinseki, Apr 17, 2014, 748 F.3d 1351\" articleviewcontext=\"article_view_related_article\" class=\"eGainArticleLink\" eg-link-click=\"\" href=\"/system/templates/selfservice/va_ssnew/help/customer/locale/en-US/portal/554400000001018/content/554400000014419/Bowers-v-Shinseki-Apr-17-2014-748-F3d-1351\"><em>Bowers v. Shinseki</em></a>, 748 F.3d. 1351 (Fed. Cir., 2014), the Federal Circuit held that active duty for training does not qualify as active military, naval, air, or space service for the purpose of establishing entitlement to SC for ALS on a presumptive basis.</span></span></div><div><span style=\"font-family: arial, helvetica, sans-serif\"><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><span style=\"font-size: 14px\"><strong><em> </em></strong></span></span></span></span></div><div><span style=\"font-family: arial, helvetica, sans-serif\"><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><span style=\"font-size: 14px\"><strong><em>Note</em></strong>:  Primary lateral sclerosis (PLS) is <strong><em>not</em></strong> considered to be a qualifying </span><span style=\"font-size: 14px\">disease under <a href=\"http://www.ecfr.gov/cgi-bin/text-idx?SID=061a0b481382fdc4ff5c1697742e7858&amp;node=se38.1.3_1318&amp;rgn=div8\" target=\"_blank\">38 CFR 3.318</a>.  Because PLS and ALS are diseases of the nervous system and both affect motor neurons, treating physicians may not be able to identify whether the Veteran has PLS or ALS in the initial stages.  If the diagnosis is uncertain after reviewing the medical evidence, request a medical opinion with examiner review of <em>all</em> pertinent evidence in the claims folder.   </span></span></span></span></div><div><span style=\"font-family: arial, helvetica, sans-serif\"><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><span style=\"font-size: 14px\"> </span></span></span></span></span></span></div><div><span style=\"font-family: arial, helvetica, sans-serif\"><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><span style=\"font-size: 14px\">This was considered a liberalizing regulation.  Therefore consider the application of <a href=\"http://www.ecfr.gov/cgi-bin/text-idx?SID=055c1bf4970910e4b257cfd824ce0b59&amp;node=se38.1.3_1114&amp;rgn=div8\" target=\"_blank\">38 CFR 3.114(a)</a> when granting presumptive SC for ALS under the provisions of <a href=\"http://www.ecfr.gov/cgi-bin/text-idx?SID=061a0b481382fdc4ff5c1697742e7858&amp;node=se38.1.3_1318&amp;rgn=div8\" target=\"_blank\">38 CFR 3.318</a>.</span></span></span></span></span></span></div><div><span style=\"font-family: arial, helvetica, sans-serif\"><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><span style=\"font-size: 14px\"><strong><em> </em></strong></span></span></span></span></span></span></span></span></div><div><span style=\"font-family: arial, helvetica, sans-serif\"><span style=\"font-size: 14px\"><strong><em>References</em></strong>:  For more information on </span></span></div><ul><li><span style=\"font-family: arial, helvetica, sans-serif\"><span style=\"font-size: 14px\">liberalizing changes of law and Department of Veterans Affairs (VA) issuances, see </span></span><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><a articleid=\"554400000180492\" articlename=\"M21-1, Part V, Subpart ii, Chapter 4, Section A - Effective Dates\" articleviewcontext=\"article_view_related_article\" class=\"eGainArticleLink\" eg-link-click=\"\" href=\"/system/templates/selfservice/va_ssnew/help/customer/locale/en-US/portal/554400000001018/content/554400000180492/M21-1-Part-V-Subpart-ii-Chapter-4-Section-A-Effective-Dates\">M21-1, Part V, Subpart ii, 4.A.6</a></span></span></li><li><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">authority to decide ALS claims, see <a href=\"#2f\" target=\"_self\">M21-1, Part V, Subpart iii, 12.C.2.f</a>, and</span></span></li><li><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">active duty service for establishing entitlement to SC for ALS on a presumptive basis, see <a articleid=\"554400000099950\" articlename=\"Hansen-Sorensen v. Wilkie, Dec 11, 2018, 909 F.3d 1379\" articleviewcontext=\"article_view_related_article\" class=\"eGainArticleLink\" eg-link-click=\"\" href=\"/system/templates/selfservice/va_ssnew/help/customer/locale/en-US/portal/554400000001018/content/554400000099950/Hansen-Sorensen-v-Wilkie-Dec-11-2018-909-F3d-1379\"><em>Hansen-Sorensen v. Wilkie</em></a>, 909 F.3d 1379 (Fed. Cir. 2018).</span></span></li></ul></div></td></tr></tbody></table><div class=\"ng-scope\" style=\"margin-left: 85pt\"><hr/></div><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"ng-scope\" style=\"border-spacing: 0px; border-collapse: revert;\"><tbody><tr><td style=\"height: 123px; width: 115px; vertical-align: top; padding: 0px;\"><h3><span style=\"font-family: arial, helvetica, sans-serif\"><span style=\"font-size: 14px\">V.iii.12.C.2.c<a id=\"2c\" name=\"2c\">.</a>  Assigning a 100 Percent Minimum Evaluation for ALS</span></span></h3></td><td style=\"height: 123px; width: 15px; vertical-align: top; padding: 0px;\"></td><td style=\"height: 123px; width: 516px; padding: 0px;\"><div><span style=\"font-family: arial, helvetica, sans-serif\"><span style=\"font-size: 14px\">ALS is evaluated under <a href=\"http://www.ecfr.gov/cgi-bin/text-idx?SID=f0aa74b3307a3ad4b8794ead73ecfa75&amp;node=se38.1.4_1124a&amp;rgn=div8\" target=\"_blank\">38 CFR 4.124a, DC 8017</a>.</span></span></div><div><span style=\"font-family: arial, helvetica, sans-serif\"><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><span style=\"font-size: 14px\"> </span></span></span></span></div><div><span style=\"font-family: arial, helvetica, sans-serif\"><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><span style=\"font-size: 14px\">Effective January 19, 2012, the diagnostic criteria for ALS were amended in <a href=\"http://www.ecfr.gov/cgi-bin/text-idx?SID=9848eb68e4a8ab1f8810e3e8a8acd53c&amp;node=se38.1.4_1124a&amp;rgn=div8\" target=\"_blank\">38 CFR 4.124a</a> to provide a 100-percent evaluation for any Veteran with service-connected (SC) ALS.  A diagnosis of ALS alone is sufficient to support an evaluation of 100 percent.  A total disability evaluation is the minimum evaluation to be assigned for ALS because of the possibility of SMC and automatic entitlement to ancillary benefits.</span></span></span></span></div><div><span style=\"font-family: arial, helvetica, sans-serif\"><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><span style=\"font-size: 14px\"><strong><em> </em></strong></span></span></span></span></span></span></div><div><span style=\"font-family: arial, helvetica, sans-serif\"><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><span style=\"font-size: 14px\"><strong><em>Note</em></strong>:  This rule will be applied to all cases pending before VA on or after, January 19, 2012, and <strong><em>does</em></strong> constitute a liberalizing VA regulation under <a href=\"https://www.law.cornell.edu/uscode/text/38/5110\" target=\"_blank\">38 U.S.C. 5110(g)</a> and <a href=\"http://www.ecfr.gov/cgi-bin/text-idx?SID=2c083629815e61850d4f981fea53b185&amp;node=se38.1.3_1114&amp;rgn=div8\" target=\"_blank\">38 CFR 3.114</a> for the purpose of determinations of effective dates and retroactive benefits.</span></span></span></span></span></span></div></td></tr></tbody></table><div class=\"ng-scope\" style=\"margin-left: 85pt\"><hr/></div><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"ng-scope\" style=\"border-spacing: 0px; border-collapse: revert;\"><tbody><tr><td style=\"width: 115px; vertical-align: top; padding: 0px;\"><h3><span style=\"font-family: arial, helvetica, sans-serif\"><span style=\"font-size: 14px\">V.iii.12.C.2.d<a id=\"2d\" name=\"2d\">.</a>  Evaluation Guidelines for ALS</span></span></h3></td><td style=\"width: 15px; vertical-align: top; padding: 0px;\"></td><td style=\"width: 516px; padding: 0px;\"><div><span style=\"font-family: arial, helvetica, sans-serif\"><span style=\"font-size: 14px\">Determine the proper evaluation for all complications of ALS prior to coding a single 100-percent evaluation under <a href=\"http://www.ecfr.gov/cgi-bin/text-idx?SID=f0aa74b3307a3ad4b8794ead73ecfa75&amp;node=se38.1.4_1124a&amp;rgn=div8\" target=\"_blank\">38 CFR 4.124a, DC 8017</a>.  Refer to the table below for guidance.</span></span></div><div><span style=\"font-family: arial, helvetica, sans-serif\"><span style=\"font-size: 14px\"> </span></span></div><table border=\"1\" cellpadding=\"1\" cellspacing=\"1\" style=\"width: 482px; border-spacing: 1px; border-collapse: revert;\" summary=\"This is an If-Then table.  Column 1 provides the criteria and column 2 provides the actions to take to determine the proper evaluation for all complications of ALS prior to coding a single 100 percent evaluation under 38 CFR 4.124a, DC 8017.\" width=\"482\"><thead><tr><th scope=\"col\" style=\"width: 50%; padding: 1px;\"><div align=\"left\"><span style=\"font-family: arial, helvetica, sans-serif\"><span style=\"font-size: 14px\"><strong>If ...</strong></span></span></div></th><th scope=\"col\" style=\"width: 50%; padding: 1px;\"><div align=\"left\"><span style=\"font-family: arial, helvetica, sans-serif\"><span style=\"font-size: 14px\"><strong>Then ...</strong></span></span></div></th></tr></thead><tbody><tr><td style=\"width: 50%; vertical-align: top; text-align: left; padding: 1px;\"><div><span style=\"font-family: arial, helvetica, sans-serif\"><span style=\"font-size: 14px\">there is no complication warranting a single 100-percent evaluation</span></span></div></td><td style=\"width: 50%; padding: 1px;\"><ul><li><div><span style=\"font-family: arial, helvetica, sans-serif\"><span style=\"font-size: 14px\">assign a 100-percent evaluation under <a href=\"http://www.ecfr.gov/cgi-bin/text-idx?SID=f0aa74b3307a3ad4b8794ead73ecfa75&amp;node=se38.1.4_1124a&amp;rgn=div8\" target=\"_blank\">38 CFR 4.124a, DC 8017</a>, and</span></span></div></li><li><div><span style=\"font-family: arial, helvetica, sans-serif\"><span style=\"font-size: 14px\">include all compensable complications in the description of the diagnosis.</span></span></div></li></ul><div><span style=\"font-family: arial, helvetica, sans-serif\"><span style=\"font-size: 14px\"><strong><em>Example</em></strong>:  ALS with loss of use of the left foot and partial ninth cranial nerve paralysis.</span></span></div></td></tr><tr><td style=\"width: 50%; vertical-align: top; text-align: left; padding: 1px;\"><div><span style=\"font-family: arial, helvetica, sans-serif\"><span style=\"font-size: 14px\">a single 100-percent evaluation is warranted for a complication of ALS</span></span></div></td><td style=\"width: 50%; padding: 1px;\"><ul><li><div><span style=\"font-family: arial, helvetica, sans-serif\"><span style=\"font-size: 14px\">assign a 100-percent evaluation for that complication.</span></span></div><ul><li><div><span style=\"font-family: arial, helvetica, sans-serif\"><span style=\"font-size: 14px\">Use a hyphenated DC.</span></span></div></li><li><div><span style=\"font-family: arial, helvetica, sans-serif\"><span style=\"font-size: 14px\"><strong><em>Example</em></strong>:  8017-5110, loss of use of both feet.</span></span></div></li></ul></li><li><div><span style=\"font-family: arial, helvetica, sans-serif\"><span style=\"font-size: 14px\">Separately evaluate additional complications.</span></span></div></li><li><div><span style=\"font-family: arial, helvetica, sans-serif\"><span style=\"font-size: 14px\">Do not assign a separate evaluation under <a href=\"http://www.ecfr.gov/cgi-bin/text-idx?SID=f0aa74b3307a3ad4b8794ead73ecfa75&amp;node=se38.1.4_1124a&amp;rgn=div8\" target=\"_blank\">38 CFR 4.124a, DC 8017</a> alone; this would be pyramiding under <a href=\"http://www.ecfr.gov/cgi-bin/text-idx?SID=061a0b481382fdc4ff5c1697742e7858&amp;node=se38.1.4_114&amp;rgn=div8\" target=\"_blank\">38 CFR 4.14</a>. </span></span></div></li></ul><div><span style=\"font-family: arial, helvetica, sans-serif\"><span style=\"font-size: 14px\"><strong><em>Note</em></strong>:  A 100-percent evaluation for a complication of ALS satisfies the policy that all ALS awards will be assigned at least a 100-percent evaluation.</span></span></div></td></tr></tbody></table><div></div><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><strong><em>Reference</em></strong>:  For more information on evaluating ALS, see <a href=\"https://vbaw.vba.va.gov/bl/21/rating/rat00.htm\" target=\"_blank\"><em>Suggested Diagnostic Codes for Parkinson's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS)</em></a>.</span></span></div></td></tr></tbody></table><div class=\"ng-scope\" style=\"margin-left: 85pt\"><hr/></div><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"ng-scope\" style=\"border-spacing: 0px; border-collapse: revert;\"><tbody><tr><td style=\"width: 115px; vertical-align: top; padding: 0px;\"><h3><span style=\"font-family: arial, helvetica, sans-serif\"><span style=\"font-size: 14px\">V.iii.12.C.2.e<a id=\"2e\" name=\"2e\">.</a>   ALS and Ancillary Benefits</span></span></h3></td><td style=\"width: 15px; vertical-align: top; padding: 0px;\"></td><td style=\"width: 516px; padding: 0px;\"><div><span style=\"font-family: arial, helvetica, sans-serif\"><span style=\"font-size: 14px\">Consider eligibility for SMC and/or other ancillary benefits in all ALS cases. </span></span></div><ul><li><div><span style=\"font-family: arial, helvetica, sans-serif\"><span style=\"font-size: 14px\">Ensure the <em>Codesheet</em> reflects all complications that can be separately evaluated.</span></span></div></li><li><div><span style=\"font-family: arial, helvetica, sans-serif\"><span style=\"font-size: 14px\">Entitlement to SMC at the statutory housebound rate may be warranted when</span></span></div><ul><li><div><span style=\"font-family: arial, helvetica, sans-serif\"><span style=\"font-size: 14px\">ALS and complications are assigned one 100-percent evaluation under <a href=\"http://www.ecfr.gov/cgi-bin/text-idx?SID=061a0b481382fdc4ff5c1697742e7858&amp;node=se38.1.4_1124a&amp;rgn=div8\" target=\"_blank\">38 CFR 4.124a, DC 8017</a> and the combined evaluation of other SC conditions totals 60 percent or higher, or</span></span></div></li><li><div><span style=\"font-family: arial, helvetica, sans-serif\"><span style=\"font-size: 14px\">an ALS complication is evaluated as 100-percent disabling and the combined evaluation of other SC conditions, including additional separately evaluated complications of ALS, total 60 percent or higher. </span></span></div></li></ul></li><li><div><span style=\"font-family: arial, helvetica, sans-serif\"><span style=\"font-size: 14px\">Entitlement to SMC, such as SMC K for loss of use of a foot, may still be warranted when one total disability evaluation is assigned for ALS and all complications under <a href=\"http://www.ecfr.gov/cgi-bin/text-idx?SID=f0aa74b3307a3ad4b8794ead73ecfa75&amp;node=se38.1.4_1124a&amp;rgn=div8\" target=\"_blank\">38 CFR 4.124a, DC 8017</a>.</span></span></div></li><li><div><span style=\"font-family: arial, helvetica, sans-serif\"><span style=\"font-size: 14px\">Effective December 3, 2013, <a href=\"http://www.ecfr.gov/cgi-bin/text-idx?SID=061a0b481382fdc4ff5c1697742e7858&amp;node=se38.1.3_1809&amp;rgn=div8\" target=\"_blank\">38 C.F.R. 3.809d</a> provides that SC ALS is a qualifying condition for the purpose of entitlement to specially adapted housing.</span></span></div></li><li><div><span style=\"font-family: arial, helvetica, sans-serif\"><span style=\"font-size: 14px\">Effective February 25, 2015, <a href=\"http://www.ecfr.gov/cgi-bin/text-idx?SID=061a0b481382fdc4ff5c1697742e7858&amp;node=se38.1.3_1808&amp;rgn=div8\" target=\"_blank\">38 CFR 3.808</a> provides that SC ALS is a qualifying condition for entitlement to a certificate of eligibility for automobile or other conveyance and adaptive equipment.  The amendment applies to all applications pending before VA on, or received after, February 25, 2015.</span></span></div></li></ul><div><span style=\"font-family: arial, helvetica, sans-serif\"><span style=\"font-size: 14px\"><strong><em>References</em></strong>:  For more information on</span></span></div><ul><li><div><span style=\"font-family: arial, helvetica, sans-serif\"><span style=\"font-size: 14px\">SMC, see <a articleid=\"554400000177480\" articlename=\"M21-1, Part VIII, Subpart iv, Chapter 4, Section A - Special Monthly Compensation (SMC)\" articleviewcontext=\"article_view_related_article\" class=\"eGainArticleLink\" eg-link-click=\"\" href=\"/system/templates/selfservice/va_ssnew/help/customer/locale/en-US/portal/554400000001018/content/554400000177480/M21-1-Part-VIII-Subpart-iv-Chapter-4-Section-A-Special-Monthly-Compensation-SMC\">M21-1, Part VIII, Subpart iv, 4.A</a></span></span></div></li><li><div><span style=\"font-family: arial, helvetica, sans-serif\"><span style=\"font-size: 14px\">ancillary benefits, see <a articleid=\"554400000181485\" articlename=\"M21-1, Part I, Subpart ii, Chapter 2 - Department of Veterans Affairs (VA) Benefit Programs\" articleviewcontext=\"article_view_related_article\" class=\"eGainArticleLink\" eg-link-click=\"\" href=\"/system/templates/selfservice/va_ssnew/help/customer/locale/en-US/portal/554400000001018/content/554400000181485/M21-1-Part-I-Subpart-ii-Chapter-2-Department-of-Veterans-Affairs-VA-Benefit-Programs\">M21-1, Part I, Subpart ii, 2.4</a></span></span></div></li><li><div><span style=\"font-family: arial, helvetica, sans-serif\"><span style=\"font-size: 14px\">automobile allowance and adaptive equipment, see <a articleid=\"554400000173638\" articlename=\"M21-1, Part XIII, Subpart i, Chapter 2, Section A - Automobile and Adaptive Equipment Allowance Under 38 U.S.C. Chapter 39\" articleviewcontext=\"article_view_related_article\" class=\"eGainArticleLink\" eg-link-click=\"\" href=\"/system/templates/selfservice/va_ssnew/help/customer/locale/en-US/portal/554400000001018/content/554400000173638/M21-1-Part-XIII-Subpart-i-Chapter-2-Section-A-Automobile-and-Adaptive-Equipment-Allowance-Under-38-USC-Chapter-39\">M21-1, Part XIII, Subpart i, 2.A</a>, and</span></span></div></li><li><div><span style=\"font-family: arial, helvetica, sans-serif\"><span style=\"font-size: 14px\">specially adapted housing or special housing adaptation grants, see <a articleid=\"554400000173639\" articlename=\"M21-1, Part XIII, Subpart i, Chapter 2, Section B - Specially Adapted Housing (SAH) or Special Home Adaptation (SHA) Grants\" articleviewcontext=\"article_view_related_article\" class=\"eGainArticleLink\" eg-link-click=\"\" href=\"/system/templates/selfservice/va_ssnew/help/customer/locale/en-US/portal/554400000001018/content/554400000173639/M21-1-Part-XIII-Subpart-i-Chapter-2-Section-B-Specially-Adapted-Housing-SAH-or-Special-Home-Adaptation-SHA-Grants\">M21-1, Part XIII, Subpart i, 2.B</a>.</span></span></div></li></ul></td></tr></tbody></table><div class=\"ng-scope\" style=\"margin-left: 85pt\"><hr/></div><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"ng-scope\" style=\"border-spacing: 0px; border-collapse: revert;\"><tbody><tr><td style=\"width: 115px; vertical-align: top; padding: 0px;\"><h3><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">V.iii.12.C.2.f<a id=\"2f\" name=\"2f\">.</a>  Authority to Decide ALS Claims</span></span></h3></td><td style=\"height: 8px; width: 15px; padding: 0px;\"></td><td style=\"width: 516px; vertical-align: top; padding: 0px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">All claims involving ALS and/or related complications must be reviewed/rated by a Rating Veterans Service Representative designated as an ALS specialist. </span></span></div></td></tr></tbody></table><div class=\"ng-scope\" style=\"margin-left: 85pt\"><hr/></div><div class=\"ng-scope\"><br/><span style=\"font-family: arial, helvetica, sans-serif\"> </span></div><h2 class=\"ng-scope\"><span style=\"font-family: arial, helvetica, sans-serif\"> <strong><span style=\"font-size: 16px\">3<a id=\"3\" name=\"3\">.</a>  Parkinson's Disease and Parkinsonism</span></strong></span></h2><div class=\"ng-scope\"><span style=\"font-family: arial, helvetica, sans-serif\"> </span></div><div class=\"ng-scope\"><span style=\"font-family: arial, helvetica, sans-serif\"> </span></div><div class=\"ng-scope\" style=\"margin-left: 85pt\"><hr/></div><div class=\"ng-scope\" style=\"height: 8px; width: 15px\"></div><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"ng-scope\" style=\"border-spacing: 0px; border-collapse: revert;\"><tbody><tr><td style=\"width: 115px; vertical-align: top; padding: 0px;\"><h3><span style=\"font-family: arial, helvetica, sans-serif\"><span style=\"font-size: 14px\"><strong>Introduction</strong></span></span></h3></td><td style=\"width: 15px; vertical-align: top; padding: 0px;\"></td><td style=\"width: 516px; padding: 0px;\"><div><div><span style=\"font-family: arial, helvetica, sans-serif\"><span style=\"font-size: 14px\">This topic contains information on Parkinson’s disease, including</span></span></div><ul><li><div><span style=\"font-family: arial, helvetica, sans-serif\"><span style=\"font-size: 14px\">definition of </span></span></div><ul><li><div><span style=\"font-family: arial, helvetica, sans-serif\"><a href=\"#3a\" target=\"_self\"><span style=\"font-size: 14px\">Parkinson’s disease</span></a>, and</span></div></li><li><div><a href=\"#3b\" target=\"_self\"><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">Parkinsonism</span></span></a></div></li></ul></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><a href=\"#3c\" target=\"_self\"><span style=\"font-size: 14px\">SC for Parkinson’s disease and Parkinsonism</span></a></span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><span style=\"font-size: 14px\"><a href=\"#3d\" target=\"_self\">evaluating Parkinson’s disease and Parkinsonism</a>, and</span></span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><span style=\"font-size: 14px\"><a href=\"#3e\" target=\"_self\">SMC and Parkinson’s disease/Parkinsonism</a>.</span></span></span></div></li></ul></div></td></tr></tbody></table><div class=\"ng-scope\" style=\"margin-left: 85pt\"><hr/></div><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"ng-scope\" style=\"border-spacing: 0px; border-collapse: revert;\"><tbody><tr><td style=\"width: 115px; vertical-align: top; padding: 0px;\"><h3><span style=\"font-family: arial, helvetica, sans-serif\"><span style=\"font-size: 14px\"><strong>Change Date</strong></span></span></h3></td><td style=\"width: 15px; vertical-align: top; padding: 0px;\"></td><td style=\"width: 516px; padding: 0px;\"><div><span style=\"font-family: arial, helvetica, sans-serif\"><span style=\"font-size: 14px\">June 21, 2021</span></span></div></td></tr></tbody></table><div class=\"ng-scope\" style=\"margin-left: 85pt\"><hr/></div><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"ng-scope\" style=\"border-spacing: 0px; border-collapse: revert;\"><tbody><tr><td style=\"width: 115px; vertical-align: top; padding: 0px;\"><h3><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">V.iii.12.C.3.a<a id=\"3a\" name=\"3a\">.</a>  Definition: Parkinson’s Disease</span></span></h3></td><td style=\"width: 15px; vertical-align: top; padding: 0px;\"></td><td style=\"width: 516px; padding: 0px;\"><div><span style=\"font-family: arial, helvetica, sans-serif\"><span style=\"font-size: 14px\"><strong><em>Parkinson’s disease</em> </strong>is a chronic, slowly progressive central nervous system disorder characterized by muscular rigidity, a tremor of resting muscles, slow and decreased voluntary movements and positional instability.  An outdated term for Parkinson’s disease is paralysis agitans. </span></span></div><div><span style=\"font-family: arial, helvetica, sans-serif\"><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><span style=\"font-size: 14px\"> </span></span></span></span></div><div><span style=\"font-family: arial, helvetica, sans-serif\"><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><span style=\"font-size: 14px\">Early signs and symptoms of the condition may include:</span></span></span></span></div><ul><li><div><span style=\"font-family: arial, helvetica, sans-serif\"><span style=\"font-size: 14px\">infrequent blinking</span></span></div></li><li><div><span style=\"font-family: arial, helvetica, sans-serif\"><span style=\"font-size: 14px\">lack of facial expression</span></span></div></li><li><div><span style=\"font-family: arial, helvetica, sans-serif\"><span style=\"font-size: 14px\">decreased movement, and</span></span></div></li><li><div><span style=\"font-family: arial, helvetica, sans-serif\"><span style=\"font-size: 14px\">impaired postural reflexes. </span></span></div></li></ul><div><span style=\"font-family: arial, helvetica, sans-serif\"><span style=\"font-size: 14px\">The condition is characterized by muscle tremors at rest which diminish during movement and are absent during sleep.  The tremors are enhanced by emotional tension or fatigue and the hands are most affected. Muscle rigidity may be present without tremors.  As the muscle rigidity progresses, movement becomes slow (bradykinesia), decreased or diminished (hypokinesia), and difficult to initiate (akinesia).  Other signs and symptoms may include:</span></span></div><ul><li><div><span style=\"font-family: arial, helvetica, sans-serif\"><span style=\"font-size: 14px\">muscular aches and fatigue</span></span></div></li><li><div><span style=\"font-family: arial, helvetica, sans-serif\"><span style=\"font-size: 14px\">mask-like expression with open mouth</span></span></div></li><li><div><span style=\"font-family: arial, helvetica, sans-serif\"><span style=\"font-size: 14px\">drooling</span></span></div></li><li><div><span style=\"font-family: arial, helvetica, sans-serif\"><span style=\"font-size: 14px\">stooped posture</span></span></div></li><li><div><span style=\"font-family: arial, helvetica, sans-serif\"><span style=\"font-size: 14px\">gait characterized by involuntary, short, accelerating steps</span></span></div></li><li><div><span style=\"font-family: arial, helvetica, sans-serif\"><span style=\"font-size: 14px\">difficulty in walking</span></span></div></li><li><div><span style=\"font-family: arial, helvetica, sans-serif\"><span style=\"font-size: 14px\">loss of postural reflexes (tendency to fall forward or backward with respective shift in center of gravity)</span></span></div></li><li><div><span style=\"font-family: arial, helvetica, sans-serif\"><span style=\"font-size: 14px\">speech manifestations – specifically low speech volume with stuttering or slurred speech, or uniformity of tone and high pitch, and</span></span></div></li><li><div><span style=\"font-family: arial, helvetica, sans-serif\"><span style=\"font-size: 14px\">dysphagia.  </span></span></div></li></ul></td></tr></tbody></table><div class=\"ng-scope\" style=\"margin-left: 85pt\"><hr/></div><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"ng-scope\" style=\"border-spacing: 0px; border-collapse: revert;\"><tbody><tr><td style=\"width: 115px; vertical-align: top; padding: 0px;\"><h3><span style=\"font-family: arial, helvetica, sans-serif\"><span style=\"font-size: 14px\">V.iii.12.C.3.b<a id=\"3b\" name=\"3b\">.</a> Definition: Parkinsonism</span></span></h3></td><td style=\"width: 15px; vertical-align: top; padding: 0px;\"></td><td style=\"width: 516px; padding: 0px;\"><div><span style=\"font-family: arial, helvetica, sans-serif\"><span style=\"font-size: 14px\">Parkinsonism is a disease process separate and distinct from Parkinson’s disease.  Also called <i>atypical Parkinson’s disease or Parkinson’s plus</i>, it is a general term that refers to a group of neurological disorders that cause movement problems similar to those seen in Parkinson’s disease, as discussed in <a href=\"#3a\" target=\"_self\">M21-1, Part V, Subpart iii, 12.C.3.a</a>.</span></span></div></td></tr></tbody></table><div class=\"ng-scope\" style=\"margin-left: 85pt\"><hr/></div><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"ng-scope\" style=\"border-spacing: 0px; border-collapse: revert;\"><tbody><tr><td style=\"width: 115px; vertical-align: top; padding: 0px;\"><h3><span style=\"font-family: arial, helvetica, sans-serif\"><span style=\"font-size: 14px\">V.iii.12.C.3.c<a id=\"3c\" name=\"3c\">.</a>  SC for Parkinson’s Disease and Parkinsonism</span></span></h3></td><td style=\"width: 15px; vertical-align: top; padding: 0px;\"></td><td id=\"cke_tmp_1167\" style=\"width: 516px; padding: 0px;\"><div><span style=\"font-family: arial, helvetica, sans-serif\"><span style=\"font-size: 14px\">Parkinson’s disease or Parkinsonism can be directly incurred in service, but in most cases, either will be SC on a presumptive or secondary basis. </span></span></div><ul><li><div><span style=\"font-family: arial, helvetica, sans-serif\"><span style=\"font-size: 14px\">Paralysis agitans is listed as a chronic disease in <a href=\"http://www.ecfr.gov/cgi-bin/retrieveECFR?gp=&amp;SID=1f70c803177009695a79a5f92fb550df&amp;mc=true&amp;r=SECTION&amp;n=se38.1.3_1309\" target=\"_blank\">38 CFR 3.309(a)</a> and as such Parkinson’s disease is presumed to have had its inception in service if manifested to a compensable degree within one year of discharge under <a href=\"http://www.ecfr.gov/cgi-bin/text-idx?SID=1f70c803177009695a79a5f92fb550df&amp;mc=true&amp;node=se38.1.3_1307&amp;rgn=div8\" target=\"_blank\">38 CFR 3.307(a)(3)</a>. </span></span></div></li><li><div><span style=\"font-family: arial, helvetica, sans-serif\"><span style=\"font-size: 14px\">Parkinson’s disease is listed as a disease associated with exposure to certain herbicide agents in <a href=\"http://www.ecfr.gov/cgi-bin/retrieveECFR?gp=&amp;SID=1f70c803177009695a79a5f92fb550df&amp;mc=true&amp;r=SECTION&amp;n=se38.1.3_1309\" target=\"_blank\">38 CFR 3.309(e)</a> and therefore is presumed to be related to herbicide exposure in the Republic of Vietnam (RVN) when manifested to a compensable degree at any time after service as provided in <a href=\"http://www.ecfr.gov/cgi-bin/text-idx?SID=1f70c803177009695a79a5f92fb550df&amp;mc=true&amp;node=se38.1.3_1307&amp;rgn=div8\" target=\"_blank\">38 CFR 3.307(a)(6)</a> or <a href=\"https://www.law.cornell.edu/uscode/text/38/1116A\" target=\"_blank\">38 U.S.C. 1116A</a>.</span></span></div></li><li><div><span style=\"font-family: arial, helvetica, sans-serif\"><span style=\"font-size: 14px\"><em>Public Law 116-283, William M. (Mac) Thornberry National Defense Authorization Act for Fiscal Year 2021</em>, effective January 1, 2021, established a presumption of SC for Parkinsonism as related to herbicide exposure in the RVN when manifested to a compensable degree at any time after service as provided in <a href=\"http://www.ecfr.gov/cgi-bin/text-idx?SID=1f70c803177009695a79a5f92fb550df&amp;mc=true&amp;node=se38.1.3_1307&amp;rgn=div8\" target=\"_blank\">38 CFR 3.307(a)(6)</a> or <a href=\"https://www.law.cornell.edu/uscode/text/38/1116A\" target=\"_blank\">38 U.S.C. 1116A</a>.</span></span></div></li><li><div><span style=\"font-family: arial, helvetica, sans-serif\"><span style=\"font-size: 14px\">Finally, under <a href=\"http://www.ecfr.gov/cgi-bin/text-idx?SID=f0aa74b3307a3ad4b8794ead73ecfa75&amp;node=se38.1.3_1310&amp;rgn=div8\" target=\"_blank\">38 CFR 3.310(d)</a>, Parkinson’s disease and/or Parkinsonism is treated as secondary to traumatic brain injury (TBI) when the TBI was moderate or severe.  </span></span></div></li></ul><div><span style=\"font-family: arial, helvetica, sans-serif\"><span style=\"font-size: 14px\"><strong><em>References</em></strong>:  For more information on</span></span></div><ul><li><div><span style=\"font-family: arial, helvetica, sans-serif\"><span style=\"font-size: 14px\">presumptive SC, see <a articleid=\"554400000180482\" articlename=\"M21-1, Part V, Subpart ii, Chapter 2, Section B - Presumptive Service Connection (SC)\" articleviewcontext=\"article_view_related_article\" class=\"eGainArticleLink\" eg-link-click=\"\" href=\"/system/templates/selfservice/va_ssnew/help/customer/locale/en-US/portal/554400000001018/content/554400000180482/M21-1-Part-V-Subpart-ii-Chapter-2-Section-B-Presumptive-Service-Connection-SC\">M21-1, Part V, Subpart ii, 2.B</a></span></span></div></li><li><div><span style=\"font-family: arial, helvetica, sans-serif\"><span style=\"font-size: 14px\">conditions presumptively related to herbicide exposure in the RVN, see </span></span></div><ul><li><div><span style=\"font-family: arial, helvetica, sans-serif\"><span style=\"font-size: 14px\"><a href=\"https://www.ecfr.gov/cgi-bin/text-idx?SID=f21d0b79764b69b65893677eebba89d7&amp;mc=true&amp;node=se38.1.3_1309&amp;rgn=div8\" target=\"_blank\">39 CFR 3.309(e)</a>, and </span></span></div></li><li><div><span style=\"font-family: arial, helvetica, sans-serif\"><span style=\"font-size: 14px\"><a articleid=\"554400000177422\" articlename=\"M21-1, Part VIII, Subpart i, Chapter 1, Section A - Developing Claims for Service Connection (SC) Based on Herbicide Exposure\" articleviewcontext=\"article_view_related_article\" class=\"eGainArticleLink\" eg-link-click=\"\" href=\"/system/templates/selfservice/va_ssnew/help/customer/locale/en-US/portal/554400000001018/content/554400000177422/M21-1-Part-VIII-Subpart-i-Chapter-1-Section-A-Developing-Claims-for-Service-Connection-SC-Based-on-Herbicide-Exposure\">M21-1, Part VIII, Subpart i</a></span></span></div></li></ul></li><li><div><span style=\"font-family: arial, helvetica, sans-serif\"><span style=\"font-size: 14px\">secondary SC of conditions related to TBI, see <a articleid=\"554400000180832\" articlename=\"M21-1, Part V, Subpart iii, Chapter 12, Section B - Traumatic Brain Injury (TBI)\" articleviewcontext=\"article_view_related_article\" class=\"eGainArticleLink\" eg-link-click=\"\" href=\"/system/templates/selfservice/va_ssnew/help/customer/locale/en-US/portal/554400000001018/content/554400000180832/M21-1-Part-V-Subpart-iii-Chapter-12-Section-B-Traumatic-Brain-Injury-TBI\">M21-1, Part V, Subpart iii, 12.B</a></span></span></div></li><li><div><span style=\"font-family: arial, helvetica, sans-serif\"><span style=\"font-size: 14px\">considering whether a medical diagnosis has probative value, see <a articleid=\"554400000014383\" articlename=\"M21-1, Part V, Subpart ii, Chapter 1, Section A - Principles of Reviewing and Weighing Evidence\" articleviewcontext=\"article_view_related_article\" class=\"eGainArticleLink\" eg-link-click=\"\" href=\"/system/templates/selfservice/va_ssnew/help/customer/locale/en-US/portal/554400000001018/content/554400000014383/M21-1-Part-V-Subpart-ii-Chapter-1-Section-A-Principles-of-Reviewing-and-Weighing-Evidence\">M21-1, Part V, Subpart ii, 1.A</a></span></span></div></li><li><div><span style=\"font-family: arial, helvetica, sans-serif\"><span style=\"font-size: 14px\">determining whether to require further development, see <a articleid=\"554400000180487\" articlename=\"M21-1, Part V, Subpart ii, Chapter 3, Section B - Making Partial Rating Decisions\" articleviewcontext=\"article_view_related_article\" class=\"eGainArticleLink\" eg-link-click=\"\" href=\"/system/templates/selfservice/va_ssnew/help/customer/locale/en-US/portal/554400000001018/content/554400000180487/M21-1-Part-V-Subpart-ii-Chapter-3-Section-B-Making-Partial-Rating-Decisions\">M21-1, Part V, Subpart ii, 3.B.1.a</a>, and</span></span></div></li><li><div><span style=\"font-family: arial, helvetica, sans-serif\"><span style=\"font-size: 14px\">determining whether examinations are insufficient for rating purposes and obtaining clarification, see <a articleid=\"554400000180517\" articlename=\"M21-1, Part IV, Subpart i, Chapter 3, Section C - Insufficient Examinations\" articleviewcontext=\"article_view_related_article\" class=\"eGainArticleLink\" eg-link-click=\"\" href=\"/system/templates/selfservice/va_ssnew/help/customer/locale/en-US/portal/554400000001018/content/554400000180517/M21-1-Part-IV-Subpart-i-Chapter-3-Section-C-Insufficient-Examinations\">M21-1, Part IV, Subpart i, 3.C</a>.</span></span></div></li></ul></td></tr></tbody></table><div class=\"ng-scope\" style=\"margin-left: 85pt\"><hr/></div><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"ng-scope\" style=\"border-spacing: 0px; border-collapse: revert;\"><tbody><tr><td style=\"width: 115px; vertical-align: top; padding: 0px;\"><h3><span style=\"font-family: arial, helvetica, sans-serif\"><span style=\"font-size: 14px\">V.iii.12.C.3.d<a id=\"3d\" name=\"3d\">.</a>  Evaluating Parkinson’s Disease and Parkinsonism</span></span></h3></td><td style=\"width: 15px; vertical-align: top; padding: 0px;\"></td><td id=\"cke_tmp_1207\" style=\"width: 516px; padding: 0px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">Evaluate </span></span></div><ul><li><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">Parkinson's disease using the diagnostic criteria for paralysis agitans under <a href=\"http://www.ecfr.gov/cgi-bin/text-idx?SID=4d2799ea334d81a09ed89c14f1cbbecd&amp;mc=true&amp;node=se38.1.4_1124a&amp;rgn=div8\" target=\"_blank\">38 CFR. 4.124a, DC 8004</a>, and</span></span></li><li><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">Parkinsonism by analogy to paralysis agitans under <a href=\"http://www.ecfr.gov/cgi-bin/text-idx?SID=4d2799ea334d81a09ed89c14f1cbbecd&amp;mc=true&amp;node=se38.1.4_1124a&amp;rgn=div8\" target=\"_blank\">38 CFR. 4.124a, DC 8004</a>, using DC 8099-8004. </span></span></li></ul><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">Use the same rating guidance as for MS as provided in <a href=\"#1b\" target=\"_self\">M21-1, Part V, Subpart iii, 12.C.1.b</a>.  </span></span></div><div></div><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><strong><em>Reference</em></strong>:  For more information on evaluating Parkinson’s disease, see <a href=\"https://vbaw.vba.va.gov/bl/21/rating/rat00.htm\" target=\"_blank\"><em>Suggested Diagnostic Codes for Parkinson's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS)</em></a>.</span></span></div></td></tr></tbody></table><div class=\"ng-scope\" style=\"margin-left: 85pt\"><hr/></div><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"ng-scope\" style=\"border-spacing: 0px; border-collapse: revert;\"><tbody><tr><td style=\"width: 115px; vertical-align: top; padding: 0px;\"><h3><span style=\"font-family: arial, helvetica, sans-serif\"><span style=\"font-size: 14px\">V.iii.12.C.3.e<a id=\"3e\" name=\"3e\">.</a> SMC and Parkinson’s Disease/</span></span><br/><span style=\"font-family: arial, helvetica, sans-serif\"><span style=\"font-size: 14px\">Parkinsonism</span></span></h3></td><td style=\"width: 15px; vertical-align: top; padding: 0px;\"></td><td style=\"width: 516px; padding: 0px;\"><div><span style=\"font-family: arial, helvetica, sans-serif\"><span style=\"font-size: 14px\">Give careful consideration to SMC in cases of Parkinson’s disease and/or Parkinsonism, particularly losses of use and aid and attendance (A&amp;A).  </span></span></div><div><span style=\"font-family: arial, helvetica, sans-serif\"><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><span style=\"font-size: 14px\"><strong><em> </em></strong></span></span></span></span></div><div><span style=\"font-family: arial, helvetica, sans-serif\"><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><span style=\"font-size: 14px\"><strong><em>References</em></strong>:  For more information on</span></span></span></span></div><ul><li><div><span style=\"font-family: arial, helvetica, sans-serif\"><span style=\"font-size: 14px\">loss of use, see  <a articleid=\"554400000177480\" articlename=\"M21-1, Part VIII, Subpart iv, Chapter 4, Section A - Special Monthly Compensation (SMC)\" articleviewcontext=\"article_view_related_article\" class=\"eGainArticleLink\" eg-link-click=\"\" href=\"/system/templates/selfservice/va_ssnew/help/customer/locale/en-US/portal/554400000001018/content/554400000177480/M21-1-Part-VIII-Subpart-iv-Chapter-4-Section-A-Special-Monthly-Compensation-SMC\">M21-1, Part VIII, Subpart iv, 4.A.4</a>, and</span></span></div></li><li><div><span style=\"font-family: arial, helvetica, sans-serif\"><span style=\"font-size: 14px\"><span style=\"font-size: 14px\">the level of disability required for entitlement to A&amp;A, see <a articleid=\"554400000177480\" articlename=\"M21-1, Part VIII, Subpart iv, Chapter 4, Section A - Special Monthly Compensation (SMC)\" articleviewcontext=\"article_view_related_article\" class=\"eGainArticleLink\" eg-link-click=\"\" href=\"/system/templates/selfservice/va_ssnew/help/customer/locale/en-US/portal/554400000001018/content/554400000177480/M21-1-Part-VIII-Subpart-iv-Chapter-4-Section-A-Special-Monthly-Compensation-SMC\">M21-1, Part VIII, Subpart iv, 4.A.8.b</a>.</span></span></span></div></li></ul></td></tr></tbody></table><div class=\"ng-scope\" style=\"margin-left: 85pt\"><hr/></div><div class=\"ng-scope\" style=\"text-align: right\"><span style=\"font-size: 11px\"><span style=\"font-family: arial, helvetica, sans-serif\"><a articleid=\"554400000180832\" articlename=\"M21-1, Part V, Subpart iii, Chapter 12, Section B - Traumatic Brain Injury (TBI)\" articleviewcontext=\"article_view_related_article\" class=\"eGainArticleLink\" eg-link-click=\"\" href=\"/system/templates/selfservice/va_ssnew/help/customer/locale/en-US/portal/554400000001018/content/554400000180832/M21-1-Part-V-Subpart-iii-Chapter-12-Section-B-Traumatic-Brain-Injury-TBI\">﻿﻿</a></span></span></div><div class=\"ng-scope\" style=\"text-align: right\"><span style=\"font-size: 11px\"><span style=\"font-family: arial, helvetica, sans-serif\"><a articleid=\"554400000180832\" articlename=\"M21-1, Part V, Subpart iii, Chapter 12, Section B - Traumatic Brain Injury (TBI)\" articleviewcontext=\"article_view_related_article\" class=\"eGainArticleLink\" eg-link-click=\"\" href=\"/system/templates/selfservice/va_ssnew/help/customer/locale/en-US/portal/554400000001018/content/554400000180832/M21-1-Part-V-Subpart-iii-Chapter-12-Section-B-Traumatic-Brain-Injury-TBI\">&lt;-- Previous Section</a>  <a articleid=\"554400000180520\" articlename=\"M21-1, Part V, Subpart iii, Chapter 13 - Mental Disorders\" articleviewcontext=\"article_view_related_article\" class=\"eGainArticleLink\" eg-link-click=\"\" href=\"/system/templates/selfservice/va_ssnew/help/customer/locale/en-US/portal/554400000001018/content/554400000180520/M21-1-Part-V-Subpart-iii-Chapter-13-Mental-Disorders\">Next Section --&gt;</a></span></span></div><div class=\"ng-scope\"><span style=\"font-family: arial, helvetica, sans-serif\"><a href=\"#top\" target=\"_self\"><span style=\"font-size: 11px\">To Top</span></a></span></div><p class=\"ng-scope\"></p></div>\n</div>",
  "external_links": [
    "http://www.ecfr.gov/cgi-bin/retrieveECFR?gp=&SID=1f70c803177009695a79a5f92fb550df&mc=true&r=SECTION&n=se38.1.3_1309",
    "http://www.ecfr.gov/cgi-bin/text-idx?SID=039d52e6f928e64a4c69be720bd18f4e&mc=true&node=se38.1.3_1309&rgn=div8",
    "http://www.ecfr.gov/cgi-bin/text-idx?SID=055c1bf4970910e4b257cfd824ce0b59&node=se38.1.3_1114&rgn=div8",
    "http://www.ecfr.gov/cgi-bin/text-idx?SID=061a0b481382fdc4ff5c1697742e7858&node=se38.1.3_1307&rgn=div8",
    "http://www.ecfr.gov/cgi-bin/text-idx?SID=061a0b481382fdc4ff5c1697742e7858&node=se38.1.3_1318&rgn=div8",
    "http://www.ecfr.gov/cgi-bin/text-idx?SID=061a0b481382fdc4ff5c1697742e7858&node=se38.1.3_1808&rgn=div8",
    "http://www.ecfr.gov/cgi-bin/text-idx?SID=061a0b481382fdc4ff5c1697742e7858&node=se38.1.3_1809&rgn=div8",
    "http://www.ecfr.gov/cgi-bin/text-idx?SID=061a0b481382fdc4ff5c1697742e7858&node=se38.1.4_1124a&rgn=div8",
    "http://www.ecfr.gov/cgi-bin/text-idx?SID=061a0b481382fdc4ff5c1697742e7858&node=se38.1.4_114&rgn=div8",
    "http://www.ecfr.gov/cgi-bin/text-idx?SID=1f70c803177009695a79a5f92fb550df&mc=true&node=se38.1.3_1307&rgn=div8",
    "http://www.ecfr.gov/cgi-bin/text-idx?SID=2c083629815e61850d4f981fea53b185&node=se38.1.3_1114&rgn=div8",
    "http://www.ecfr.gov/cgi-bin/text-idx?SID=4d2799ea334d81a09ed89c14f1cbbecd&mc=true&node=se38.1.4_1124a&rgn=div8",
    "http://www.ecfr.gov/cgi-bin/text-idx?SID=9848eb68e4a8ab1f8810e3e8a8acd53c&node=se38.1.4_1124a&rgn=div8",
    "http://www.ecfr.gov/cgi-bin/text-idx?SID=e296a722064811bf99fb83cca8e57a8b&mc=true&node=se38.1.3_1350&rgn=div8",
    "http://www.ecfr.gov/cgi-bin/text-idx?SID=f0aa74b3307a3ad4b8794ead73ecfa75&node=se38.1.3_1310&rgn=div8",
    "http://www.ecfr.gov/cgi-bin/text-idx?SID=f0aa74b3307a3ad4b8794ead73ecfa75&node=se38.1.4_1124a&rgn=div8",
    "https://vbaw.vba.va.gov/bl/21/rating/rat00.htm",
    "https://www.ecfr.gov/cgi-bin/text-idx?SID=f21d0b79764b69b65893677eebba89d7&mc=true&node=se38.1.3_1309&rgn=div8",
    "https://www.law.cornell.edu/uscode/text/38/1114",
    "https://www.law.cornell.edu/uscode/text/38/1116A",
    "https://www.law.cornell.edu/uscode/text/38/5110"
  ],
  "scraped_at": "2025-06-16T22:46:21.735242",
  "next_section": "https://www.knowva.ebenefits.va.gov/system/templates/selfservice/va_ssnew/help/customer/locale/en-US/portal/554400000001018/content/554400000180520/M21-1-Part-V-Subpart-iii-Chapter-13-Mental-Disorders"
}